Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Operating Expenses (2020 - 2022)

Atea Pharmaceuticals has reported Operating Expenses over the past 3 years, most recently at $39.9 million for Q4 2022.

  • Quarterly results put Operating Expenses at $39.9 million for Q4 2022, down 43.8% from a year ago — trailing twelve months through Dec 2022 was $130.6 million (down 38.66% YoY), and the annual figure for FY2025 was $180.9 million, down 6.25%.
  • Operating Expenses for Q4 2022 was $39.9 million at Atea Pharmaceuticals, up from $16.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for AVIR hit a ceiling of $71.0 million in Q4 2021 and a floor of $4.0 million in Q1 2020.
  • Median Operating Expenses over the past 3 years was $33.8 million (2021), compared with a mean of $33.6 million.
  • Biggest five-year swings in Operating Expenses: surged 773.42% in 2021 and later tumbled 70.38% in 2022.
  • Atea Pharmaceuticals' Operating Expenses stood at $28.0 million in 2020, then skyrocketed by 153.69% to $71.0 million in 2021, then plummeted by 43.8% to $39.9 million in 2022.
  • The last three reported values for Operating Expenses were $39.9 million (Q4 2022), $16.3 million (Q3 2022), and $32.3 million (Q2 2022) per Business Quant data.